At Pfizer, we discover and develop novel vaccines that help protect people around the world from deadly viruses and bacteria. In 2018, we focused on rational vaccine design — understanding the structure of proteins enabled by high-tech tools like cryo-electron microscopy as a basis to design and produce those proteins for use in vaccines.
Latest Corporate Responsibility Report Demonstrates Progress on Environmental and Social Issues while Supporting Customers and Communities
August 5, 2019 /3BL Media/ - Comerica Incorporated (NYSE: CMA) recently released its 2018 Comerica Corporate Responsibility Report which can be found at www.comerica.com/sustainability. Comerica President and CEO Curtis C. Farmer stated, “Corporate responsibility is a fundamental part of Comerica’s culture. Our Corporate Responsibility Report provides insights on how we support a successful business climate, the environment and our communities, all of which combined put us on a path towards a thriving future.”
While we may not be a household name, Alliance Data engages with millions of consumers across the globe every day through our notable list of FORTUNE 1000 clients. Executing excellence in data-driven loyalty marketing solutions also means delivering on critical responsibilities to ensure the secure and responsible use of data, adhering to responsible lending practices and providing an unwavering commitment to service.
Pfizer is committed to ensuring that the manufacturing, use and disposal of our products, including antibiotics, does not adversely affect human health or the environment. Core to this commitment is taking action to assess and reduce, as needed, the risk of antibiotics in wastewater from Pfizer and supplier manufacturing facilities
We live in challenging, often contentious times, with political, cultural and environmental issues constantly brewing. Companies across industries face the daunting task of appropriately responding to issues and news on a regular basis, and to help guide our responses at Pfizer, we developed our Social Framework – a way to determine if, when, how and why we will address a societal issue.
We are experiencing an exciting new era in drug discovery and development with scientific advances that could result in future breakthroughs. To make this promise a reality, Pfizer is dedicated to investing in manufacturing capabilities to keep pace with science today, and to plan for what’s coming next.
Today, Pfizer released the 2018 Annual Review highlighting the ways that patients are the driving force behind every aspect of the company’s business in its mission to deliver innovative medicines and vaccines that help improve health and well-being at every stage of life.
This year, the integrated report explores how Pfizer’s work keeps Patients at Our Center. Highlights include:
In Africa, patients can outnumber doctors 3,000 to 1. That’s one of the reasons why Pfizer is dedicated to fostering innovative partnerships that allow us to mobilize resources to help find new and unique solutions that increase access to needed health care.
Our colleague Willy Soriney, Strategic Partnership Director, works in Kenya using the science of partnerships to look for new approaches that can speed access to critical health interventions and fill unmet medical needs, bringing quality health care to those who need it most.
Antimicrobial resistance (AMR), or the ability of a bacterium, virus, or fungus to develop resistance to the medicines commonly used to treat them, is one of the leading global public health threats today. Currently, AMR causes more than 700,000 deaths annually. If left unchecked, this number is expected to rise to 10 million deaths annually by 2050. In collaboration with the infectious disease community, we are working to develop solutions that address and help treat the serious and growing AMR crisis.